Resin composition for non-conductive films having excellent high-temperature properties for 3D TSV packages

A resin composition with imidazoles having latent thermal activity addresses thermal stability issues in conventional resins, providing a cured film with improved DSC temperatures for reliable thermal compression bonding in 3D TSV packages.

KR103046686B1Active Publication Date: 2026-11-11HENKEL KGAA
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
KR1020247004148
Authority / Receiving Office
KR · KR
Patent Type
Patents
Current Assignee / Owner
Priority Date
2021-07-21
Filing Date
2022-07-21
Publication Date
2026-11-11
Estimated Expiration
2042-07-21

AI Technical Summary

Technical Problem

Conventional resin compositions containing maleimide-containing resins face issues such as material trapping and solder extrusion problems during thermal compression bonding processes due to inadequate DSC initiation and peak temperatures, which are below the required thermal stability thresholds.

Method used

A composition comprising one or more resins, one or more imidazoles with latent thermal activity, one or more inorganic fillers, and one or more additives, which results in a cured film with improved thermal stability, characterized by a DSC initiation temperature of at least 145°C and a peak temperature of at least 150°C, suitable for thermal compression bonding processes.

Benefits of technology

The composition achieves enhanced thermal stability and reliability in 3D TSV packages by preventing solder extrusion and material trapping, ensuring effective bonding and electrical interconnection.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 112024013867566-PCT00001
    Figure 112024013867566-PCT00001
  • Figure 112024013867566-PCT00002
    Figure 112024013867566-PCT00002
  • Figure 112024013867566-PCT00003
    Figure 112024013867566-PCT00003
Patent Text Reader

Abstract

The present disclosure relates to a composition for forming a film and to the use of said film in a three-dimensional silicon-through-via (3D TSV) package. In a particular aspect, the present disclosure relates to a composition comprising one or more resins, one or more imidazoles having latent thermal activity, one or more inorganic fillers, and one or more additives, a B-stage film prepared from the disclosed composition, and a cured film obtained after curing of the disclosed composition.
Need to check novelty before this filing date? Find Prior Art

Description

Technology Field

[0001] Aspects of the present disclosure relate to compositions for forming films and the use of said films in three-dimensional silicon-through-via (3D TSV) packages. In a particular aspect, the present disclosure relates to a composition comprising one or more resins, one or more imidazoles having latent thermal activity, one or more inorganic fillers, and one or more additives, a B-stage film prepared from the disclosed composition, and a cured film obtained after curing the disclosed composition. In a particular aspect, the cured film obtained after curing the disclosed composition has specific physical properties and / or a combination of physical properties. In a particular aspect, the present disclosure relates to an underfill film prepared from the disclosed composition, e.g., a wafer-level underfill film (WAUF). Embodiments of the disclosed film are suitable for use, for example, in a thermal compression bonding process. Background Technology

[0002] With the anticipation of next-generation high-performance 3D TSV packages, the materials industry faces the need to improve the high-temperature properties of film materials (e.g., underfill film materials). Realizing these goals can bring benefits such as higher thermal stability and, consequently, higher reliability in applications across the automotive, computing, networking, and telecommunications industries. Characteristics associated with the improved high-temperature properties of film materials include a relatively high Tg (glass transition temperature), a relatively low CTE (coefficient of thermal expansion), and a relatively high elastic modulus, for example, at 250°C.

[0003] Problems have been encountered when using films made from certain conventional resin compositions containing maleimide-containing resins in a hot press bonding process. For example, in some cases, B-stage films made from certain conventional resin compositions containing maleimide-containing resins may have a DSC initiation temperature of less than 100°C to 150°C. When such B-stage films are used in a hot press bonding process where the bond head contact temperature is 100°C to 150°C (e.g., as occurs in a process where the bond head contact temperature is 130°C to 210°C), material trapping problems may occur in the solder joint. In other cases, B-stage films made from conventional resin compositions containing maleimide-containing resins may have a DSC initiation temperature higher than the melting temperature of the solder (e.g., lead-free solder), e.g., a DSC initiation temperature higher than 217°C. When such B-stage films are used in a thermal compression bonding process, in some cases, solder extrusion problems may occur. In some cases, solder extrusion problems may also occur when a B-stage film made from a conventional resin composition containing one or more maleimide-containing resins has a ΔT from the DSC start temperature to the DSC peak temperature, for example, greater than 20°C, e.g., about 40°C.

[0004] At least in light of the considerations discussed above, there is interest in a composition comprising one or more resins, one or more inorganic fillers and one or more additives, a B-stage film prepared from said composition, and a cured film obtained after curing said composition, wherein said composition comprises one or more imidazoles having latent thermal activity. As used herein, an imidazole having latent thermal activity refers to an imidazole that, when combined with 1.0 g of NC-3000-L epoxy resin (Nippon Kayaku) in an amount of 0.20 g, produces a composition that exhibits a DSC initiation temperature of at least 145°C and a DSC peak temperature of at least 150°C when measured from room temperature to 300°C in N2 on a TA Instruments Thermal Analyzer DSC Q20 at a gradient rate of 10°C / min. For example, in some embodiments, an imidazole having potential thermal activity exhibits a DSC initiation temperature of at least 145°C, at least 150°C, at least 155°C, at least 160°C, at least 165°C, at least 170°C, at least 175°C, or at least 180°C when analyzed as described above. For example, in some embodiments, an imidazole having latent thermal activity exhibits a DSC initiation temperature of 145°C to 180°C, e.g., 145°C to 175°C, 145°C to 170°C, 145°C to 160°C, 150°C to 180°C, 150°C to 175°C, 150°C to 170°C, 150°C to 160°C, 155°C to 175°C, 155°C to 170°C, or 155°C to 165°C when analyzed as described above. In some embodiments, an imidazole having latent thermal activity exhibits a DSC peak temperature of at least 150°C, at least 155°C, at least 160°C, at least 165°C, at least 170°C, at least 175°C, or at least 185°C when analyzed as described above.For example, in some embodiments, an imidazole having latent thermal activity exhibits a DSC peak temperature of 150°C to 185°C, e.g., 150°C to 180°C, 150°C to 175°C, 150°C to 170°C, 150°C to 165°C, 150°C to 160°C, 160°C to 180°C, 165°C to 175°C, or 160°C to 170°C when analyzed as described above.

[0005] To avoid doubt, it should be understood that the DSC onset temperature and / or DSC peak temperature exhibited by the composition prepared and measured as described above (i.e., a composition comprising 0.20 g of imidazole having latent thermal activity and 1.0 g of NC-3000-L epoxy resin (Nippon Kayaku)) may be the same as or different from the DSC onset temperature and / or DSC peak temperature exhibited by a composition comprising the same imidazole having latent thermal activity but with other components, such as one or more resins, one or more inorganic fillers, and / or one or more additives.

[0006] In some embodiments, the imidazole having latent thermal activity is an encapsulated imidazole having latent thermal activity. As used herein, the term “encapsulated imidazole having latent thermal activity” is an imidazole that produces a composition in which (a) it is associated with an outer layer and / or barrier, and (b) when combined with 1.0 g of NC-3000-L epoxy resin (Nippon Kayaku) in an amount of 0.20 g, it exhibits a DSC initiation temperature of at least 145°C and a DSC peak temperature of at least 150°C when measured on a TA Instruments Thermal Analyzer DSC Q20 from room temperature to 300°C in N2 at a gradient rate of 10°C / min. To avoid doubt, where the imidazole having latent thermal activity is an encapsulated imidazole having latent thermal activity, the amount of 0.20 g should be understood to refer to the amount of encapsulated imidazole (i.e., the amount of 0.20 g comprises the mass of the imidazole and the coating).

[0007] By comparison, certain imidazoles do not constitute imidazoles having potential thermal activity within the meaning of the present disclosure. Such imidazoles include those that produce a composition exhibiting a DSC onset temperature of less than 145°C and a DSC peak temperature of less than 150°C when measured on a TA Instruments Thermal Analyzer DSC Q20 in N2 from room temperature to 300°C and at a gradient rate of 10°C / min, whether or not they are associated with an outer layer and / or barrier. To avoid doubt, it should be understood that even if the imidazole is encapsulated (i.e., associated with an outer layer and / or barrier), it may not still be an "encapsulated imidazole having potential thermal activity" within the meaning of the present disclosure because it exhibits a DSC onset temperature of less than 145°C and a DSC peak temperature of less than 150°C.

[0008] As a non-limiting example, four types of imidazoles were analyzed as described above. Specifically, four separate experiments were performed. In each experiment, 0.20 g of one of imidazole A, imidazole B, imidazole C, and imidazole D was combined with 1.0 g of NC-3000-L epoxy resin (Nippon Kayaku), and the resulting composition was measured on a TA Instruments Thermal Analyzer DSC Q20 in N2 from room temperature to 300°C at a gradient rate of 10°C / min. The DSC onset temperature and DSC peak temperature were measured. The results are shown in the table below. Imidazole A is 2-phenylimidazole. Imidazole B is 2-ethyl-4-methyl-1H-imidazole-1-propaninitrile. Neither imidazole A nor imidazole B associated with the outer layer and / or barrier; Therefore, neither Imidazole A nor Imidazole B is "encapsulated imidazole having latent thermal activity" within the meaning of the present disclosure. Each of Imidazole C and Imidazole D is an encapsulated imidazole having latent thermal activity of the type considered by the present disclosure.

[0009]

[0010] 1 Test conditions: 0.20 g of each imidazole was combined with 1.0 g of NC-3000-L epoxy resin (Nippon Kayaku), and each of the resulting compositions was analyzed using a TA Instruments Thermal Analyzer DSC Q20 at room temperature up to 300°C in N2 at a gradient rate of 10°C / min.

[0011] As indicated above, when analyzed as described above, compositions comprising imidazole A or imidazole B each exhibited a DSC onset temperature of less than 145°C and a DSC peak temperature of less than 150°C, whereas compositions comprising imidazole C or imidazole D each exhibited a DSC onset temperature of at least 145°C and a DSC peak temperature of at least 150°C. Accordingly, the analysis described above provides a method for determining whether an imidazole associated with an outer layer and / or barrier constitutes an "encapsulated imidazole having potential thermal activity" within the meaning of the present disclosure: when applied to the analysis described above, if a composition exhibits a DSC onset temperature of at least 145°C and a DSC peak temperature of at least 150°C, the imidazole associated with an outer layer and / or barrier constitutes an "encapsulated imidazole having potential thermal activity" within the meaning of the present disclosure; Conversely, if the composition exhibits a DSC onset temperature of less than 145°C and a DSC peak temperature of less than 150°C, the imidazole associated with the outer layer and / or barrier does not constitute "encapsulated imidazole having potential thermal activity" within the meaning of the present disclosure.

[0012] Embodiments of the disclosed composition solve the problems discussed above. For example, embodiments of an underfill film prepared from the disclosed composition are suitable for a thermal compression bonding process, such as a thermal compression bonding process for 3D TSV lamination applications. Additionally, embodiments of an underfill film prepared from the disclosed composition exhibit one or more of excellent die corner coverage, gap filling, and electrical interconnection joint formation.

[0013] In some embodiments, aspects of the present disclosure relate to the following:

[0014] 1. A composition comprising the following:

[0015] One or more resins selected from the group consisting of maleimide-containing resins, nadiimide-containing resins, itaconimide-containing resins, epoxy resins, (meth)acrylate-containing resins, and phenol-containing resins,

[0016] One or more imidazoles having latent thermal activity,

[0017] One or more types of inorganic fillers, and

[0018] One or more additives selected from the group consisting of adhesion promoters and film-forming agents,

[0019] Here:

[0020] After the composition forms a film, the film has the following physical properties:

[0021] Tg > 200℃ when measured by dynamic mechanical analysis (DMA),

[0022] Storage modulus at 25℃ < 6.5 GPa,

[0023] Storage modulus at 250℃ > 0.1 GPa, and

[0024] Coefficient of thermal expansion (CTE) < 250 ppm / ℃.

[0025] 2. A composition according to Embodiment 1, wherein one or more imidazoles having latent thermal activity are one or more encapsulated imidazoles having latent thermal activity.

[0026] 3. In any of the above embodiments, the maleimide-containing resin is a compound represented by the following, or

[0027]

[0028] (Here:

[0029] Each R is independently selected from the group consisting of H and substituted or unsubstituted alkyl;

[0030] Each m is independently selected from a group consisting of 0, 1, 2, 3, or 4;

[0031] n is 0, 1, 2, 3, 4, or 5), or

[0032] A compound represented as follows

[0033]

[0034] (Here, n is 0, 1, 2, 3, 4, or 5)

[0035] Composition.

[0036] 4. In any of the above embodiments, a composition wherein the (meth)acrylate resin is represented as follows:

[0037]

[0038] Here, n is 0, 1, 2, 3, 4, or 5.

[0039] 5. In any of the above embodiments, a composition in which the epoxy resin is a compound represented by the following:

[0040]

[0041] Here, n is 0, 1, 2, 3, 4, or 5, and m is 0, 1, 2, 3, 4, or 5.

[0042] 6. A composition in any of the above embodiments, wherein, after the composition forms a film, the film has the following physical properties:

[0043] When measured by differential scanning calorimetry (DSC) at an inclined rate of 10°C / min, the DSC start temperature is 120°C to 200°C, and

[0044] Minimum film melt viscosity of 10 Pa·s to 10,000 Pa·s when measured in N2 using a DHR2 rheometer at an inclined speed of 10°C / min.

[0045] 7. A composition in any of the above embodiments, wherein after the composition forms a film, the film has a ΔT from a DSC initiation temperature of less than 20°C or less than 15°C to a DSC peak temperature.

[0046] 8. A composition in any of the above embodiments, wherein after the composition forms a film, the film has a ΔT from a DSC initiation temperature of less than 10°C or less than 5°C to a DSC peak temperature.

[0047] 9. A method for manufacturing a cured film comprising the following steps:

[0048] A step of providing a composition according to any one of embodiments 1 to 8;

[0049] A step of casting the composition into a film; and

[0050] Step of curing the film by exposing the cast film to a rising temperature.

[0051] 10. A method for manufacturing a cured film comprising the following steps:

[0052] One or more resins selected from the group consisting of maleimide-containing resins, nadiimide-containing resins, itaconimide-containing resins, epoxy resins, (meth)acrylate-containing resins, and phenol-containing resins,

[0053] One or more imidazoles having latent thermal activity,

[0054] One or more types of inorganic fillers, and

[0055] One or more additives selected from the group consisting of adhesion promoters and film-forming agents

[0056] A step of providing a composition comprising

[0057] A step of casting the composition into a film; and

[0058] Step of curing the film by exposing the cast film to a rising temperature.

[0059] 11. A method according to Embodiment 10, wherein one or more imidazoles having latent thermal activity are one or more encapsulated imidazoles having latent thermal activity.

[0060] 12. A cured film manufactured according to any one of the methods of embodiments 9 to 11.

[0061] 13. A film having the following physical properties, manufactured according to any one of the methods of embodiments 9 to 11:

[0062] Tg > 200℃ when measured by dynamic mechanical analysis (DMA),

[0063] Storage modulus at 25℃ < 5.5 GPa,

[0064] Storage modulus at 250℃ > 0.1 GPa, and

[0065] Coefficient of thermal expansion (CTE) < 250 ppm / ℃.

[0066] 14. A film that is a wafer-level underfill film (WAUF) in embodiment 12 or embodiment 13. Specific details for implementing the invention

[0067] The disclosed composition and method can be more easily understood by referring to the following detailed description.

[0068] According to the present disclosure, a composition is provided comprising one or more resins, one or more imidazoles having latent thermal activity, one or more inorganic fillers, and one or more additives. In some embodiments, one or more resins are selected from the group consisting of maleimide-containing resins, nadiimide-containing resins, itaconimide-containing resins, epoxy resins, (meth)acrylate-containing resins, and phenol-containing resins. In some embodiments, one or more additives are selected from the group consisting of adhesion promoters and film-forming agents. In some embodiments, one or more imidazoles having latent thermal activity are one or more encapsulated imidazoles having latent thermal activity.

[0069] A method for encapsulating a curing agent for use in a chemical composition to be cured is known in the relevant art, for example, as described in WO 2011 / 126702.

[0070] In some embodiments, the encapsulated imidazole (e.g., an encapsulated imidazole having latent thermal activity) is an imidazole encapsulated by a polymer coating (e.g., wherein the polymer coating forms a shell around the imidazole). In some embodiments, the polymer coating is resistant to thermal and / or chemical degradation. In some embodiments, the imidazole and / or polymer coating may undergo a change in morphology and / or expand in the presence of heat. In some embodiments, such a change in morphology is the result of melting, vaporization, and / or a change from a glassy state to a rubbery and / or liquid state.

[0071] Non-limiting examples of imidazoles that can be encapsulated (to form encapsulated imidazoles, e.g., encapsulated imidazoles having potential thermal activity) include 2-methylimidazole (Imicure AMI-2), 2-phenylimidazole (Curesol 2PZ), 2-phenyl-4-methylimidazole (Curesol 2P4MZ), 2-heptadecylimidazole (Curesol C17Z), 2-phenyl-4,5-dihydroxymethylimidazole (Curesol 2PHZ-S), and Curesol 2MZ azine.

[0072] In some embodiments, the encapsulated imidazole (e.g., encapsulated imidazole having latent thermal activity) has a particle size in the range of 1 μm to 500 μm. In some embodiments, the encapsulated imidazole (e.g., encapsulated imidazole having latent thermal activity) has a particle size in the range of 1 μm to 250 μm. In some embodiments, the encapsulated imidazole (e.g., encapsulated imidazole having latent thermal activity) has a particle size in the range of 1 μm to 200 μm.

[0073] In some embodiments, the polymeric coating used to encapsulate the imidazole is a cross-linked or high-melting-point polymer. In some embodiments, the polymeric coating used to encapsulate the imidazole is selected from poly(p-xylylene) (parylene); cross-linked epoxy, e.g., bisphenol A diglycidyl ether, bisphenol F diglycidyl ether, bisphenol A epoxy novolac, bisphenol F epoxy novolac, 3,4-epoxycyclohexyl methyl, 3,4-epoxycyclohexyl carboxylate; and cross-linked acrylate, e.g., hexanediol di(meth)acrylate, polyethylene glycol di(meth)acrylate, ethoxylated bisphenol A di(meth)acrylate, trimethylolpropane tri(meth)acrylate, pentaerythritol tri(meth)acrylate, and tricyclodecane dimethanol diacrylate.

[0074] In some embodiments, the coating is applied by deposition, an interfacial polymerization process, or a fluid bed coating operation.

[0075] In some embodiments, after the composition forms a film, the film has specific characteristics and / or properties that make the film suitable for use in a heat-press bonding process. For example, in some embodiments, after the composition forms a film, the film has a Tg > 100°C, a storage modulus < 5 GPa at 25°C, a storage modulus > 0.1 GPa at 250°C, and a coefficient of thermal expansion (CTE) < 250 ppm / °C when measured by dynamic mechanical analysis (DMA). In some embodiments, after the composition forms a B-stage film, the B-stage film has a DSC start temperature of 120°C to 250°C when measured by differential scanning calorimetry (DSC) at a gradient rate of 10°C / min (e.g., 130°C to 250°C) and a minimum film melt viscosity of 10 Pa·s to 10,000 Pa·s when measured in N2 using a DHR2 rheometer at a gradient rate of 10°C / min.

[0076] In some embodiments, after the composition forms a cured film, the cured film has a Tg of > 100°C, > 125°C, > 150°C, > 160°C, > 165°C, > 170°C, > 175°C, > 180°C, > 185°C, > 190°C, > 200°C, > 210°C, > 220°C, > 230°C, > 240°C, > 250°C, > 260°C, > 270°C, > 280°C, > 290°C, or > 300°C when measured by dynamic mechanical analysis (DMA). In some embodiments, after the composition forms a cured film, the cured film is, when measured by DMA, 100°C to 110°C, 110°C to 120°C, 120°C to 130°C, 130°C to 140°C, 140°C to 150°C, 150°C to 160°C, 160°C to 170°C, 170°C to 180°C, 180°C to 190°C, 190°C to 200°C, 200°C to 210°C, 210°C to 220°C, 220°C to 230°C, 230°C to 240°C, 240°C to 250°C, 250°C to 260°C, 260°C to 270°C, 270°C to 280°C, 280°C to It has a Tg of 290℃, or 290℃ to 300℃.

[0077] In some embodiments, after the composition forms a cured film, the cured film has a Tg of > 100°C, > 105°C, > 110°C, > 115°C, > 120°C, > 125°C, > 130°C, > 135°C, > 150°C, > 160°C, > 170°C, > 180°C, > 190°C, > 200°C, > 210°C, > 220°C, > 230°C, > 240°C, or > 250°C when measured by thermomechanical analysis (TMA). In some embodiments, after the composition forms a cured film, the cured film has a Tg of 100°C to 110°C, 110°C to 120°C, 120°C to 130°C, 130°C to 140°C, 140°C to 150°C, 150°C to 160°C, 160°C to 170°C, 170°C to 180°C, 180°C to 190°C, 190°C to 200°C, 200°C to 210°C, 210°C to 220°C, 220°C to 230°C, 230°C to 240°C, or 240°C to 250°C when measured by TMA. In some embodiments, after the composition forms a cured film, the cured film has a Tg of 130°C to 17°C, e.g. 130°C to 160°C, or 130°C to 150°C.

[0078] In some embodiments, after the composition forms a B-stage film, the B-stage film has a storage modulus at 25°C of < 3 GPa, < 3.5 GPa, < 4 GPa, < 4.5 GPa, < 5 GPa, < 5.5 GPa, < 6 GPa, or < 6.5 GPa.

[0079] In some embodiments, after the composition forms a B-stage film, the B-stage film has a storage modulus at 25°C of 2.0 GPa to 3.0 GPa, 3.0 GPa to 3.5 GPa, 3.5 GPa to 4.0 GPa, 4.0 GPa to 4.5 GPa, 4.5 GPa to 5.0 GPa, 5.0 GPa to 5.5 GPa, 5.5 GPa to 6.0 GPa, or 6.0 GPa to 6.5 GPa. In some embodiments, after the composition forms a B-stage film, the B-stage film has a storage modulus at 25°C of 3.0 GPa to 6.5 GPa. In some embodiments, after the composition forms a B-stage film, the B-stage film has a storage modulus at 25°C of 4.0 GPa to 5.5 GPa. In some embodiments, after the composition forms a B-stage film, the B-stage film has a storage modulus of 4.0 GPa to 5.0 GPa at 25°C.

[0080] In some embodiments, after the composition forms a B-stage film, the B-stage film has a storage modulus at 250°C of > 100 MPa, > 125 MPa, > 150 MPa, > 175 MPa, > 200 MPa, > 225 MPa, or > 250 MPa. In some embodiments, after the composition forms a B-stage film, the B-stage film has a storage modulus at 250°C of 100 MPa to 150 MPa, 100 MPa to 200 MPa, 150 MPa to 200 MPa, 100 MPa to 250 MPa, or 200 MPa to 250 MPa.

[0081] In some embodiments, after the composition forms a B-stage film, the B-stage film has a storage modulus at 230°C of > 100 MPa, > 125 MPa, > 150 MPa, > 175 MPa, > 200 MPa, > 225 MPa, or > 250 MPa. In some embodiments, after the composition forms a B-stage film, the B-stage film has a storage modulus at 250°C of 100 MPa to 150 MPa, 100 MPa to 200 MPa, 150 MPa to 200 MPa, 100 MPa to 250 MPa, or 200 MPa to 250 MPa.

[0082] In some embodiments, after the composition forms a cured film, the cured film has a coefficient of thermal expansion (CTE) of < 50 ppm / ℃, < 60 ppm / ℃, < 70 ppm / ℃, < 80 ppm / ℃, < 90 ppm / ℃, < 100 ppm / ℃, < 110 ppm / ℃, < 120 ppm / ℃, < 130 ppm / ℃, < 140 ppm / ℃, < 150 ppm / ℃, < 160 ppm / ℃, < 170 ppm / ℃, < 180 ppm / ℃, < 190 ppm / ℃, < 200 ppm / ℃, < 210 ppm / ℃, < 220 ppm / ℃, < 230 ppm / ℃, < 240 ppm / ℃, or < 250 ppm / ℃.

[0083] In some embodiments, after the composition forms a cured film, the cured film has a coefficient of thermal expansion (CTE) greater than Tg of < 100 ppm / °C, < 110 ppm / °C, < 120 ppm / °C, < 130 ppm / °C, < 140 ppm / °C, < 150 ppm / °C, < 160 ppm / °C, < 170 ppm / °C, < 180 ppm / °C, < 190 ppm / °C, < 200 ppm / °C, < 210 ppm / °C, < 220 ppm / °C, < 230 ppm / °C, < 240 ppm / °C, or < 250 ppm / °C. In some embodiments, after the composition forms a cured film, the cured film has a coefficient of thermal expansion (CTE) greater than Tg of 50 ppm / °C to 80 ppm / °C. In some embodiments, after the composition forms a cured film, the cured film has a coefficient of thermal expansion (CTE) at Tg greater than 60 ppm / °C to 80 ppm / °C. In some embodiments, after the composition forms a cured film, the cured film has a coefficient of thermal expansion (CTE) at Tg greater than 60 ppm / °C to 70 ppm / °C.

[0084] In some embodiments, after the composition forms a B-stage film, the B-stage film has a minimum film melt viscosity of 300 Pa·s to 6,000 Pa·s when measured N2-weighted at a gradient speed of 10°C / min using a DHR2 rheometer. In some embodiments, after the composition forms a B-stage film, the B-stage film has a minimum film melt viscosity of 300 Pa·s to 3,000 Pa·s when measured N2-weighted at a gradient speed of 10°C / min using a DHR2 rheometer. In some embodiments, after the composition forms a B-stage film, the B-stage film has a minimum film melt viscosity of 400 Pa·s to 2,000 Pa·s when measured N2-weighted at a gradient speed of 10°C / min using a DHR2 rheometer.

[0085] In some embodiments, after the composition forms a B-stage film, the B-stage film is measured using a DHR2 rheometer at an N2 weight at an inclination rate of 10°C / min at 300 Pa·s to 400 Pa·s, 400 Pa·s to 500 Pa·s, 500 Pa·s to 600 Pa·s, 600 Pa·s to 700 Pa·s, 700 Pa·s to 800 Pa·s, 800 Pa·s to 900 Pa·s, 900 Pa·s to 1,000 Pa·s, 1,000 Pa·s to 1,100 Pa·s, 1,100 Pa·s to 1,200 Pa·s, 1,200 Pa·s to 1,300 Pa·s, 1,300 Pa·s to 1,400 Pa·s, and 1,400 Pa·s to 1,500 Pa·s, 1,500 Pa·s to 1,600 Pa·s, 1,600 Pa·s to 1,700 Pa·s, 1,700 Pa·s to 1,800 Pa·s, 1,800 Pa·s to 1,900 Pa·s, 1,900 Pa·s to 2,000 Pa·s, 2,000 Pa·s to 2,100 Pa·s, 2,100 Pa·s to 2,200 Pa·s, 2,200 Pa·s to 2,300 Pa·s, 2,300 Pa·s to 2,400 Pa·s, 2,400 Pa·s to 2,500 Pa·s, 2,500 Pa·s to 2,600 Pa·s, 2,600 Pa·s to 2,700 It has a minimum film melt viscosity of Pa·s, 2,700 Pa·s to 2,800 Pa·s, 2,800 Pa·s to 2,900 Pa·s, or 2,900 Pa·s to 3,000 Pa·s.

[0086] In some embodiments, after the composition forms a B-stage film, the B-stage film has a DSC initiation temperature of 120°C to 130°C, 120°C to 150°C, 120°C to 140°C, 130°C to 140°C, 140°C to 150°C, 150°C to 160°C, 160°C to 170°C, 170°C to 180°C, 180°C to 190°C, 190°C to 200°C, 200°C to 210°C, 210°C to 220°C, 220°C to 230°C, 230°C to 240°C, or 240°C to 250°C when measured by differential scanning calorimetry (DSC) at an N2-weighted gradient rate of 10°C / min.

[0087] In some embodiments, after the composition forms a B-stage film, the B-stage film is measured by differential scanning calorimetry (DSC) at an N2 weight rate of 10°C / min to be about 120°C to 130°C, about 120°C to 150°C, about 120°C to 140°C, about 130°C to about 140°C, about 140°C to about 150°C, about 150°C to about 160°C, about 160°C to about 170°C, about 170°C to about 180°C, about 180°C to about 190°C, about 190°C to about 200°C, about 200°C to about 210°C, about 210°C to about 220°C, about 220°C to about 230°C, about 230°C to about 240°C, or about It has a DSC initiation temperature of 240℃ to about 250℃.

[0088] In some embodiments, after the composition forms a B-stage film, the B-stage film has a ΔT from the DSC start temperature to the DSC peak temperature of less than 20°C, less than 15°C, less than 10°C, or less than 5°C. In some embodiments, after the composition forms a B-stage film, the B-stage film has a ΔT from the DSC start temperature to the DSC peak temperature of 0°C to 5°C, 5°C to 10°C, 10°C to 15°C, or 15°C to 20°C. In some embodiments, after the composition forms a B-stage film, the B-stage film has a ΔT from the DSC start temperature to the DSC peak temperature of 0°C, 1°C, 2°C, 3°C, 4°C, 5°C, 6°C, 7°C, 8°C, 9°C, 10°C, 11°C, 12°C, 13°C, 14°C, 15°C, 16°C, 17°C, 18°C, 19°C, or 20°C. While not wanting to be bound by theory, ΔT from the DSC start temperature to the DSC peak temperature, which is less than 20°C, less than 15°C, less than 10°C, or less than 5°C, or between 0°C and 5°C, between 5°C and 10°C, between 10°C and 15°C, or between 15°C and 20°C, is considered to exhibit rapid curing kinetics, which prevents, for example, solder extrusion (a phenomenon that makes the composition less suitable or unsuitable for thermal compression bonding, at least in some embodiments). Conversely, while not wanting to be bound by theory, B-stage films with a ΔT from the DSC start temperature to the DSC peak temperature of 20°C or more are considered unsuitable for the thermal compression bonding process.For example, it is known that certain B-stage films prepared from a composition containing bis-maleimide resin, epoxy resin, and 4,4-diaminodiphenyl sulfone but not containing one or more imidazoles having latent thermal activity (e.g., one or more encapsulated imidazoles having latent thermal activity) exhibit a ΔT from a DSC initiation temperature of 20°C or higher to a DSC peak temperature, and, without wanting to be bound by theory, are considered unsuitable for the heat press bonding process.

[0089] In some embodiments, one or more imidazoles having latent thermal activity are included in an amount ranging from 0.5 wt% to 10 wt%. In some embodiments, one or more imidazoles having latent thermal activity are included in an amount ranging from 1 wt% to 8 wt%. In some embodiments, one or more imidazoles having latent thermal activity are included in an amount ranging from 2 wt% to 7 wt%. In some embodiments, one or more imidazoles having latent thermal activity are included in an amount ranging from 2.5 wt% to 6.5 wt%. In some embodiments, one or more imidazoles having latent thermal activity are included in an amount ranging from 3 wt% to 6 wt%. In some embodiments, one or more imidazoles having latent thermal activity are included in an amount ranging from 2.5 wt% to 4.5 wt%. In some embodiments, one or more imidazoles having latent thermal activity are included in an amount ranging from 1 wt% to 4 wt%. In some embodiments, one or more imidazoles having latent thermal activity are included in an amount ranging from 2% to 4% by weight. In some embodiments, one or more imidazoles having latent thermal activity are included in an amount ranging from 2% to 3.5% by weight. In some embodiments, one or more imidazoles having latent thermal activity are included in an amount ranging from 2% to 3% by weight. In some embodiments, one or more imidazoles having latent thermal activity are included in an amount ranging from 2.5% to 3.5% by weight. In some embodiments, one or more imidazoles having latent thermal activity mentioned in this paragraph are one or more encapsulated imidazoles having latent thermal activity.

[0090] In some embodiments, one or more imidazoles having latent thermal activity are included in an amount ranging from about 0.5 wt% to about 10 wt%. In some embodiments, one or more imidazoles having latent thermal activity are included in an amount ranging from about 1 wt% to about 8 wt%. In some embodiments, one or more imidazoles having latent thermal activity are included in an amount ranging from about 2 wt% to about 7 wt%. In some embodiments, one or more imidazoles having latent thermal activity are included in an amount ranging from about 2.5 wt% to about 6.5 wt%. In some embodiments, one or more imidazoles having latent thermal activity are included in an amount ranging from about 3 wt% to about 6 wt%. In some embodiments, one or more imidazoles having latent thermal activity are included in an amount ranging from about 2.5 wt% to about 4.5 wt%. In some embodiments, one or more imidazoles having latent thermal activity are included in an amount ranging from about 1 wt% to about 4 wt%. In some embodiments, one or more imidazoles having latent thermal activity are included in an amount ranging from about 2 weight% to about 4 weight%. In some embodiments, one or more imidazoles having latent thermal activity are included in an amount ranging from about 2 weight% to about 3.5 weight%. In some embodiments, one or more imidazoles having latent thermal activity are included in an amount ranging from about 2 weight% to about 3 weight%. In some embodiments, one or more imidazoles having latent thermal activity are included in an amount ranging from about 2.5 weight% to about 3.5 weight%. In some embodiments, one or more imidazoles having latent thermal activity mentioned in this paragraph are one or more encapsulated imidazoles having latent thermal activity.

[0091] In some embodiments, the maleimide-containing resin, the nadimide-containing resin, or the itaconimide-containing resin is each represented as follows:

[0092] , here:

[0093] m is 1 to 15, and

[0094] p is 0-15, and

[0095] Each R 2 is independently hydrogen or C 1-6 Selected from alkyls,

[0096] J is a monovalent or polyvalent radical containing organic and / or organosiloxane radicals.

[0097] In some embodiments, J is a monovalent or polyvalent radical selected from the following:

[0098] - Typically, a hydrocarbyl or substituted hydrocarbyl species having carbon atoms in the range of about 6 to about 500, wherein the hydrocarbyl species is selected from alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, alkylaryl, arylalkyl, arylalkenyl, alkenylaryl, arylalkynyl, or alkynylaryl, provided that X may be aryl only if X comprises a combination of two or more different species;

[0099] - Typically a hydrocarbylene or substituted hydrocarbylene species having carbon atoms in the range of about 6 to about 500, wherein the hydrocarbylene species is selected from alkylene, alkenylene, alkynylene, cycloalkylene, cycloalkenylene, arylene, alkylarylene, arylalkylene, arylalkenylene, alkenylarylene, arylalkynylene, or alkynylarylene,

[0100] - Substituted or unsubstituted C6-C 10 Aril;

[0101] - Heterocyclic or substituted heterocyclic species typically having carbon atoms in the range of about 6 to about 500,

[0102] - Polysiloxane,

[0103] - Polysiloxane-polyurethane block copolymer, or

[0104] - One or more of the above, and covalent bond, -O-, -S-, -NR-, -NR-C(O)-, -NR-C(O)-O-, -NR-C(O)-NR-, -SC(O)-, -SC(O)-O-, -SC(O)-NR-, -OS(O)2-, -OS(O)2-O-, -OS(O)2-NR-, -OS(O)-, -OS(O)-O-, -OS(O)-NR-, -O-NR-C(O)-, -O-NR-C(O)-O, -O-NR-C(O)-NR, -NR-OC(O)-, -NR-OC(O)-O-, -NR-OC(O)-NR-, -O-NR-C(S)-, -O-NR-C(S)-O-, -O-NR-C(S)-NR-, -NR-OC(S)-, -NR-OC(S)-O-, -NR-OC(S)-NR-, -OC(S)-, -OC(S)-O-, -OC(S)-NR-, -NR-C(S)-, -NR-C(S)-O-, -NR-C(S)-NR-, -SS(O)2-, -SS(O) 2- A combination of linkers selected from O-, -SS(O)2-NR-, -NR-OS(O)-, -NR-OS(O)-O-, -NR-OS(O)-NR-, -NR-OS(O)2-, -NR-OS(O)2-O-, -NR-OS(O)2-NR-, -O-NR-S(O)-, -O-NR-S(O)-O-, -O-NR-S(O)-NR-, -O-NR-S(O)2-O-, -O-NR-S(O)2-NR-, -O-NR-S(O)2-, -OP(O)R2-, -SP(O)R2-, or -NR-P(O)R2-; wherein each R is independently hydrogen, alkyl, or substituted alkyl.

[0105] In some embodiments, J is a substituted or unsubstituted C6-aryl, oxyalkyl, thioalkyl, aminoalkyl, carboxyalkyl, oxyalkenyl, thioalkenyl, aminoalkenyl, carboxyalkenyl, oxyalkinyl, thioalkenyl, aminoalkenyl, carboxyalkenyl, oxycycloalkyl, thiocycloalkyl, aminocycloalkyl, carboxycycloalkyl, oxycycloalkenyl, thiocycloalkenyl, aminocycloalkenyl, carboxycycloalkenyl, heterocyclic, oxyheterocyclic, thioheterocyclic, aminoheterocyclic, carboxyheterocyclic, oxyaryl, thioaryl, aminoaryl, carboxyaryl, heteroaryl, oxyheteroaryl, thioheteroaryl, aminoheteroaryl, carboxyheteroaryl, oxyalkylaryl, Thioalkylaryl, aminoalkylaryl, carboxyalkylaryl, oxyarylalkyl, thioarylalkyl, aminoarylalkyl, carboxyarylalkyl, oxyarylalkenyl, thioarylalkenyl, aminoarylalkenyl, carboxyarylalkenyl, oxyalkenylaryl, thioalkenylaryl, aminoalkenylaryl, carboxyalkenylaryl, oxyarylalkenyl, thioalkenylaryl, thioarylalkenyl, aminoarylalkenyl, carboxyarylalkenyl, oxyalkenylalkenyl, thioalkenylaryl, aminoalkenylaryl or carboxyalkenylaryl, oxyalkylene, thioalkylene, aminoalkylene, carboxyalkylene, oxyalkenylene, thioalkenylene, aminoalkenylene, carboxyalkenylene, oxyalkenylene, thioalkenylene, aminoalkenylene, Carboxyalkynylene, oxycycloalkylene, thiocycloalkylene, aminocycloalkylene, carboxycycloalkylene, oxycycloalkenylene, thiocycloalkenylene, aminocycloalkenylene, carboxycycloalkenylene, oxyalalkylene, thioarylene, aminoarylene, carboxyarylene, thioarylene, aminoarylene, carboxyarylene, oxyalkylarylene, thioalkylarylene, aminoalkylarylene, carboxyalkylarylene, oxyarylalkylene, thioarylalkylene, aminoarylalkylene, carboxyarylalkylene, oxyalkenylalkylene, thioarylalkylene, aminoarylalkylene, carboxyarylalkylene, oxyalkenylalkenylene, thioarylalkenylene, aminoarylalkenylene, carboxyarylalkenylene, thioarylkenylarylene, aminoalkenylarylene, carboxyalkenylarylene, oxyalkenylalkenylene, thioarylalkenylene, aminoalkenylarylene, carboxyalkenylarylene, oxyalkenylalkynylene, thioarylalkynylene, Aminoaryl alkynylene, Carboxyaryl alkynylene, Oxyalkynylarylene,Thioalkynylarylene, aminoalkynylarylene, carboxyalkynylarylene, heteroarylene, oxyheteroarylene, thioheteroarylene, aminoheteroarylene, carboxyheteroarylene, heteroatom-containing divalent or polyvalent cyclic moiety, oxyheteroatom-containing divalent or polyvalent cyclic moiety, thioheteroatom-containing divalent or polyvalent cyclic moiety, aminoheteroatom-containing divalent or polyvalent cyclic moiety, or carboxyheteroatom-containing divalent or polyvalent cyclic moiety.

[0106] In some embodiments, the maleimide-containing resin is represented as follows:

[0107]

[0108] Here:

[0109] Each R is independently selected from the group consisting of H and substituted or unsubstituted alkyl;

[0110] Each m is independently selected from the group consisting of 0, 1, 2, 3, and 4;

[0111] n is 0, 1, 2, 3, 4, and 5.

[0112] In some embodiments, the composition comprises a compound represented by the following:

[0113] .

[0114] This compound is BMI-5100 (chemical name: 3,3'-dimethyl-5,5'-diethyl-4,4'-diphenylmethane bismaleimide; Daiwa Kasei, Japan), which is a compound with an average number molecular weight of about 300 as tested by gel permeation chromatography (GPC).

[0115] In some embodiments, the maleimide-containing resin is represented as follows:

[0116]

[0117] Here, n is 0, 1, 2, 3, 4, or 5.

[0118] In some embodiments, the maleimide-containing resin is a BMI resin having 180 to 400 maleimide equivalents. A maleimide equivalent is the weight (grams) of a resin containing 1 equivalent of a maleimide functional group. In some embodiments, the maleimide-containing resin is a BMI resin having 220 maleimide equivalents. In some embodiments, the maleimide-containing resin is a BMI resin having 300 maleimide equivalents. In some embodiments, the maleimide-containing resin is a BMI resin having about 400 maleimide equivalents. In some embodiments, the maleimide-containing resin is a BMI resin having about 390 to about 400 maleimide equivalents. In some embodiments, the maleimide-containing resin is a BMI resin having 390 to 400 maleimide equivalents.

[0119] In some embodiments, the maleimide-containing resin is included in an amount ranging from about 1 wt% to about 20 wt%. In some embodiments, the maleimide-containing resin is included in an amount ranging from about 1 wt% to about 15 wt%. In some embodiments, the maleimide-containing resin is included in an amount ranging from about 3 wt% to about 15 wt%. In some embodiments, the maleimide-containing resin is included in an amount ranging from about 1 wt% to about 5 wt%. In some embodiments, the maleimide-containing resin is included in an amount ranging from about 5 wt% to about 20 wt%. In some embodiments, the maleimide-containing resin is included in an amount ranging from about 5 wt% to about 15 wt%. In some embodiments, the maleimide-containing resin is included in an amount ranging from about 10 wt% to about 20 wt%. In some embodiments, the maleimide-containing resin is included in an amount ranging from about 10 wt% to about 15 wt%. In some embodiments, the maleimide-containing resin is included in an amount ranging from about 12 wt% to about 17 wt%. In some embodiments, the maleimide-containing resin is included in about 10 wt%, about 11 wt%, about 12 wt%, about 13 wt%, about 14 wt%, about 15 wt%, about 16 wt%, about 17 wt%, about 18 wt%, about 19 wt%, or about 20 wt%.

[0120] In some embodiments, the itaconimide-containing resin is represented as follows:

[0121] ,

[0122] Here, Ar is a substituted or unsubstituted aryl group.

[0123] In some embodiments, the itaconimide-containing resin is as follows:

[0124] .

[0125] In some embodiments, nadimide is represented as follows:

[0126] ,

[0127] Here:

[0128] - Ar is a substituted or unsubstituted aryl, and

[0129] - R is selected from the group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.

[0130] The composition of the present disclosure comprises, among other components as mentioned above, one or more epoxy resins. A wide variety of epoxy-functionalized resins, such as liquid-type epoxy resins based on bisphenol A, solid-type epoxy resins based on bisphenol A, liquid-type epoxy resins based on bisphenol F (e.g., Epiclone EXA-835LV), polyfunctional epoxy resins based on phenol-novolak resin, dicyclopentadiene-type epoxy resins (e.g., Epiclone HP-7200L), naphthalene-type epoxy resins, as well as any two or more mixtures of these, are considered for use in the present invention.

[0131] Exemplary epoxy-functionalized resins considered for use herein include diepoxides of cycloaliphatic alcohols, hydrogenated bisphenol A (commercially available as Epalloy 5000), difunctional cycloaliphatic glycidyl esters of hexahydrophthalic anhydride (commercially available as Epalloy 5200), Epiclone EXA-835LV, Epiclone HP-7200L, etc., as well as mixtures of any two or more of these.

[0132] In certain embodiments, the epoxy component may comprise a combination of two or more different bisphenol-based epoxys. These bisphenol-based epoxys may be selected from bisphenol A, bisphenol F, or bisphenol S epoxys, or combinations thereof. Additionally, two or more different bisphenol epoxys (e.g., A, F, or S) within the same type of resin may be used.

[0133] Commercially available examples of bisphenol epoxy considered for use herein include bisphenol-F type epoxy (e.g., RE-404-S from Nippon Kayaku, Japan, and Epiclone 830 (RE1801), 830S (RE1815), 830A (REI 826), and 830W from Dai Nippon Ink & Chemicals, Inc., and RSL 1738 and YL-983U from Resolution and bisphenol-A type epoxy (e.g., YL-979 and 980 from Resolution).

[0134] The aforementioned bisphenol epoxy, which is commercially available from Dainippon, is recommended as a liquid undiluted epichlorohydrin-bisphenol F epoxy having a much lower viscosity than conventional epoxy based on bisphenol A epoxy, and possesses physical properties similar to liquid bisphenol A epoxy. Bisphenol F epoxy has a lower viscosity than bisphenol A epoxy, and all other things are identical between the two types of epoxy, which provides lower viscosity and thus provides a fast-flowing underfill sealant material. The EEW of these four types of bisphenol F epoxy is 165 to 180. The viscosity at 25°C is 3,000 to 4,500 cps (excluding RE1801, which has a viscosity upper limit of 4,000 cps). The hydrolyzable chloride content is reported as 200 ppm for RE1815 and 830W, and 100 ppm for RE1826.

[0135] The aforementioned bisphenol epoxy is commercially available from Resolution and is recommended as a low-chloride liquid epoxy. Bisphenol A epoxy has an EEW (g / eq) of 180 to 195 and a viscosity of 100 to 250 cps at 25°C. The total chloride content for YL-979 is reported to be 500 to 700 ppm, and the total chloride content for YL-980 is reported to be 100 to 300 ppm. Bisphenol F epoxy has an EEW (g / eq) of 165 to 180 and a viscosity of 30 to 60 at 25°C. The total chloride content for RSL-1738 is reported to be 500 to 700 ppm, and for YL-983U, 150 to 350 ppm.

[0136] In addition to bisphenol epoxy, other epoxy compounds are considered for use as epoxy components of the disclosed composition. For example, cycloaliphatic epoxy, such as 3,4-epoxycyclohexylmethyl-3,4-epoxycyclohexyl carbonate, may be used. Additionally, monofunctional, difunctional, or polyfunctional reactive diluents may be used to adjust the viscosity of the resulting resin material and / or lower its Tg. Exemplary reactive diluents include butyl glycidyl ether, cresyl glycidyl ether, polyethylene glycol glycidyl ether, polypropylene glycol glycidyl ether, etc.

[0137] Epoxy compounds suitable for use in this invention include polyglycidyl derivatives of phenolic compounds, such as EPON 828, EPON 1001, EPON 1009, and EPON 1031 from Resolution; DER 331, DER 332, DER 334, and DER 542 from Dow Chemical Co.; and those commercially available under the trade name EPON, such as BREN-S from Nippon Kayaku. Other suitable epoxy compounds include polyepoxides prepared from polyols, etc., and polyglycidyl derivatives of phenol-formaldehyde novolaks, the latter being, for example, DEN 431, DEN 438, and DEN 439 from Dow Chemical. Cresol analogs are also commercially available under the trade name Araldite, such as Araldite ECN 1235, Araldite ECN 1273, and Araldite ECN 1299 from Ciba Specialty Chemicals Corporation. SU-8 is a bisphenol A-type epoxy novolak available from Resolution. Polyglycidyl adducts of amines, amino alcohols, and polycarboxylic acids are also useful in the present invention, and commercially available resins thereof include Glyamine 135, Glyamine 125, and Glyamine 115 from FIC Corporation; Includes Araldite MY-720, Araldite 0500, and Araldite 0510 from Ciba Specialty Chemicals, and PGA-X and PGA-C from Sherwin-Williams Co.

[0138] Monofunctional epoxy co-reactant diluents suitable for optional use herein also include those having a viscosity lower than that of the epoxy component, typically less than about 250 cps. Monofunctional epoxy co-reactant diluents may have epoxy groups having alkyl groups of about 6 to about 28 carbon atoms, and examples thereof are C 6-28 Alkyl glycidyl ether, C 6-28 Fatty acid glycidyl ester, C 6-28 Includes alkylphenol glycidyl ethers, etc.

[0139] In some embodiments, the epoxy resin is novolac epoxy EEW 200, novolac epoxy EEW 300, or novolac epoxy EEW 140.

[0140] In some embodiments, the epoxy resin is a compound represented by the following:

[0141]

[0142] Here, n is 0, 1, 2, 3, 4, or 5, and m is 0, 1, 2, 3, 4, or 5.

[0143] In some embodiments, the epoxy resin is included in an amount ranging from about 1 wt% to about 30 wt%. In some embodiments, the epoxy resin is included in an amount ranging from about 1 wt% to about 25 wt%. In some embodiments, the epoxy resin is included in an amount ranging from about 1 wt% to about 20 wt%. In some embodiments, the epoxy resin is included in an amount ranging from about 1 wt% to about 15 wt%. In some embodiments, the epoxy resin is included in an amount ranging from about 3 wt% to about 15 wt%. In some embodiments, the epoxy resin is included in an amount ranging from about 1 wt% to about 5 wt%. In some embodiments, the epoxy resin is included in an amount ranging from about 5 wt% to about 20 wt%. In some embodiments, the epoxy resin is included in an amount ranging from about 5 wt% to about 15 wt%. In some embodiments, the epoxy resin is included in an amount ranging from about 10 wt% to about 20 wt%. In some embodiments, the epoxy resin is included in an amount ranging from about 15 wt% to about 30 wt%. In some embodiments, the epoxy resin is included in an amount ranging from about 15 wt% to about 25 wt%. In some embodiments, the epoxy resin is included in an amount ranging from about 10 wt% to about 15 wt%. In some embodiments, the epoxy resin is included in about 10 wt%, about 11 wt%, about 12 wt%, about 13 wt%, about 14 wt%, about 15 wt%, about 16 wt%, about 17 wt%, about 18 wt%, about 19 wt%, about 20 wt%, about 21 wt%, about 22 wt%, about 23 wt%, about 24 wt%, about 25 wt%, about 26 wt%, about 27 wt%, about 28 wt%, about 29 wt%, and about 30 wt%.

[0144] In some embodiments, the film-forming binder resin is included in an amount ranging from about 1 wt% to about 25 wt%. In some embodiments, the film-forming binder resin is included in an amount ranging from about 1 wt% to about 20 wt%. In some embodiments, the film-forming binder resin is included in an amount ranging from about 5 wt% to about 15 wt%. In some embodiments, the film-forming binder resin is included in an amount ranging from about 7 wt% to about 12 wt%. In some embodiments, the film-forming binder resin is included in an amount ranging from about 9 wt% to about 11 wt%. In some embodiments, the film-forming binder resin is included in an amount of about 5 wt%, about 6 wt%, about 7 wt%, about 8 wt%, about 9 wt%, about 10 wt%, about 11 wt%, about 12 wt%, about 13 wt%, about 14 wt%, about 15 wt%, about 16 wt%, about 17 wt%, about 18 wt%, about 19 wt%, or about 20 wt%.

[0145] The compositions of the present disclosure comprise, among other components as mentioned above, one or more (meth)acrylate-containing resins. In some embodiments, the (meth)acrylate resin is represented as follows:

[0146]

[0147] Here, n is 0, 1, 2, 3, 4, or 5.

[0148] In some embodiments, the (meth)acrylate-containing resin is included in an amount ranging from about 1 wt% to about 20 wt%. In some embodiments, the (meth)acrylate-containing resin is included in an amount ranging from about 1 wt% to about 15 wt%. In some embodiments, the (meth)acrylate-containing resin is included in an amount ranging from about 3 wt% to about 15 wt%. In some embodiments, the (meth)acrylate-containing resin is included in an amount ranging from about 1 wt% to about 5 wt%. In some embodiments, the (meth)acrylate-containing resin is included in an amount ranging from about 5 wt% to about 20 wt%. In some embodiments, the (meth)acrylate-containing resin is included in an amount ranging from about 5 wt% to about 15 wt%. In some embodiments, the (meth)acrylate-containing resin is included in an amount ranging from about 10 wt% to about 20 wt%. In some embodiments, the (meth)acrylate-containing resin is included in an amount ranging from about 10 wt% to about 15 wt%. In some embodiments, the (meth)acrylate-containing resin is included in an amount ranging from about 12 wt% to about 17 wt%. In some embodiments, the (meth)acrylate-containing resin is included in an amount of about 10 wt%, about 11 wt%, about 12 wt%, about 13 wt%, about 14 wt%, about 15 wt%, about 16 wt%, about 17 wt%, about 18 wt%, about 19 wt%, or about 20 wt%.

[0149] The composition of the present disclosure comprises, as mentioned above, one or more inorganic fillers among other components. In some embodiments, the filler is an electrically non-conductive filler, such as silica. In some embodiments, the filler is silica, calcium silicate, aluminum hydroxide, magnesium hydroxide, calcium carbonate, magnesium carbonate, aluminum oxide (Al2O3), zinc oxide (ZnO), magnesium oxide (MgO), aluminum nitride (AlN), boron nitride (BN), carbon nanotubes, diamond, clay, aluminosilicate, etc., as well as any two or more of these (or comprises).

[0150] In some embodiments, the inorganic filler is an inorganic non-conductive filler comprising particles having a maximum particle size of 5 μm or less than 5 μm. For example, in some embodiments, the filler has a particle size of about 0.1 μm to about 5 μm or 0.1 μm to 5 μm. In some embodiments, the filler loading is sufficient to meet the underfill material requirements. In some embodiments, the filler is included in an amount ranging from about 10 wt% to about 70 wt%. In some embodiments, the filler is included in an amount ranging from about 20 wt% to about 60 wt%. In some embodiments, the filler is included in an amount ranging from about 25 wt% to about 55 wt%. In some embodiments, the filler is included in an amount ranging from about 30 wt% to about 50 wt%. In some embodiments, the filler is included in an amount ranging from about 35 wt% to about 45 wt%. In some embodiments, the filler is included in an amount ranging from about 35 wt%, about 36 wt%, about 37 wt%, about 38 wt%, about 39 wt%, about 40 wt%, about 41 wt%, about 42 wt%, about 43 wt%, about 44 wt%, or about 45 wt%.

[0151] The composition of the present disclosure comprises one or more additives selected from the group consisting of adhesion promoters and film-forming agents among other components, as mentioned above.

[0152] As used herein, the term "adhesion promoter" refers to a compound that enhances the adhesive properties of the formulation into which it is introduced. Adhesion promoters may be organic or inorganic compounds and may include combinations thereof. Non-limiting examples of adhesion promoters include organic zirconate compounds, organic titanate compounds, and silane coupling agents. In some embodiments, the adhesion promoter is Z6040 from Dow.

[0153] In some embodiments, the adhesion promoter is included in an amount ranging from about 0.1 wt% to about 5 wt%. In some embodiments, the adhesion promoter is included in an amount ranging from about 0.1 wt% to about 1.0 wt%. In some embodiments, the adhesion promoter is included in an amount ranging from about 0.5 wt% to about 1.0 wt%. In some embodiments, the adhesion promoter is included in an amount ranging from about 0.5 wt% to about 1.5 wt%. In some embodiments, the adhesion promoter is included in an amount ranging from about 1 wt% to about 2 wt%, about 2 wt% to about 3 wt%, about 3 wt% to about 4 wt%, or about 4 wt% to about 5 wt%.

[0154] As used herein, the term “film-forming agent” refers to a compound that assists in the formation of a film by increasing the viscosity of the combined material, for example (as a non-limiting example). Non-limiting examples of film-forming agents include elastomeric additive components, for example, copolymerized ethylene acrylic elastomers, natural or synthetic rubbers, for example, substituted polyethylene, resins, for example, polyvinyl butyral resin and chlorosulfonated polyethylene synthetic rubber (CSM), partially cross-linked butyl rubber compounds, for example, butyl rubber products commercially available under the trade names KALAR®, DPR®, ISOLENE® and KALENE® from Royal Elastomers of New Jersey, and ethylene acrylic elastomeric materials, for example, Vamac® commercially available from DuPont Corporation. Further non-limiting examples of film-forming agents include, but are not limited to, acrylic polymers, such as butyl acrylate-ethyl acrylate-acetonitrile copolymers and ethyl acrylate-acetonitrile copolymers (e.g., polymers containing glycidyl functional groups), such as copolymers available from Nagase JP.

[0155] In some embodiments, the film-forming agent is included in an amount ranging from about 5 to about 40 weight percent. In some embodiments, the film-forming agent is included in an amount ranging from about 7.5 to about 30 weight percent. In some embodiments, the film-forming agent is included in an amount ranging from about 20 to about 30 weight percent. In some embodiments, the film-forming agent is included in an amount ranging from about 22 to about 28 weight percent. In some embodiments, the film-forming agent is included in an amount ranging from about 23 to about 26 weight percent. In some embodiments, the film-forming agent is included in an amount ranging from about 23 to about 25 weight percent. In some embodiments, the film-forming agent is included in about 24 weight percent, about 25 weight percent, or about 26 weight percent.

[0156] In some embodiments, the composition of the present disclosure further comprises one or more fluxing agents.

[0157] As used herein, the term "fluxing agent" refers to a reducing agent that prevents oxides from forming on the surface of a molten metal. Non-limiting examples of fluxing agents include compounds having at least one (meth)acrylate group and at least one carboxylic acid group, carboxylic acids (compounds having one or more acrylic acid functional groups, rosin gum, dodecandioic acid (commercially available from Aldrich as Corfree M2), adipic acid, sebacic acid, polysebacic acid polyanhydride, maleic acid, tartaric acid, citric acid, etc., but not limited thereto), alcohols, hydroxylic acids and hydroxyl bases, polyols (including but not limited to ethylene glycol, glycerol, 3-[bis(glycidyloxymethyl)methoxy]-1,2-propanediol, D-ribose, D-cellobiose, cellulose, 3-cyclohexene-1,1-dimethanol, etc.).

[0158] In some embodiments, the fluxing agent is included in an amount ranging from about 1 to about 10 weight percent. In some embodiments, the fluxing agent is included in an amount ranging from about 1 to about 5 weight percent. In some embodiments, the fluxing agent is included in an amount ranging from about 5 to about 10 weight percent. In some embodiments, the fluxing agent is included in an amount ranging from about 2 to about 8 weight percent. In some embodiments, the fluxing agent is included in an amount ranging from about 3 to about 7 weight percent. In some embodiments, the fluxing agent is included in an amount ranging from about 3 to about 5 weight percent. In some embodiments, the fluxing agent is included in an amount ranging from about 3 to about 7 weight percent. In some embodiments, the fluxing agent is included in an amount ranging from about 3 to about 7 weight percent. In some embodiments, the fluxing agent is included in an amount ranging from about 3 weight percent, about 4 weight percent, or about 5 weight percent.

[0159] An aspect of the present disclosure also relates to a method for manufacturing a B-stage film and / or a cured film.

[0160] In some embodiments, the method for manufacturing a cured film comprises the following steps:

[0161] One or more resins selected from the group consisting of maleimide-containing resins, nadiimide-containing resins, itaconimide-containing resins, epoxy resins, (meth)acrylate-containing resins, and phenol-containing resins,

[0162] One or more imidazoles having latent thermal activity,

[0163] One or more types of inorganic fillers, and

[0164] One or more additives selected from the group consisting of adhesion promoters and film-forming agents

[0165] A step of providing a composition comprising

[0166] A step of casting the composition into a film; and

[0167] Step of curing the film by exposing the cast film to a rising temperature.

[0168] In some embodiments, the method for manufacturing a cured film comprises the following steps:

[0169] One or more resins selected from the group consisting of maleimide-containing resins, nadiimide-containing resins, itaconimide-containing resins, epoxy resins, (meth)acrylate-containing resins, and phenol-containing resins,

[0170] One or more encapsulated imidazoles having potential thermal activity,

[0171] One or more types of inorganic fillers, and

[0172] One or more additives selected from the group consisting of adhesion promoters and film-forming agents

[0173] A step of providing a composition comprising

[0174] A step of casting the composition into a film; and

[0175] Step of curing the film by exposing the cast film to a rising temperature.

[0176] In some embodiments, the method for manufacturing a cured film comprises the following steps:

[0177] One or more resins selected from the group consisting of maleimide-containing resins, nadiimide-containing resins, itaconimide-containing resins, epoxy resins, (meth)acrylate-containing resins, and phenol-containing resins,

[0178] One or more imidazoles having latent thermal activity,

[0179] 1 or more types of inorganic fillers,

[0180] One or more additives selected from the group consisting of adhesion promoters and film-forming agents, and

[0181] One or more fluxing agents

[0182] A step of providing a composition comprising

[0183] A step of casting the composition into a film; and

[0184] Step of curing the film by exposing the cast film to a rising temperature.

[0185] In some embodiments, the method for manufacturing a cured film comprises the following steps:

[0186] One or more resins selected from the group consisting of maleimide-containing resins, nadiimide-containing resins, itaconimide-containing resins, epoxy resins, (meth)acrylate-containing resins, and phenol-containing resins,

[0187] One or more encapsulated imidazoles having potential thermal activity,

[0188] 1 or more types of inorganic fillers,

[0189] One or more additives selected from the group consisting of adhesion promoters and film-forming agents, and

[0190] One or more fluxing agents

[0191] A step of providing a composition comprising

[0192] A step of casting the composition into a film; and

[0193] Step of curing the film by exposing the cast film to a rising temperature.

[0194] In some embodiments of the method for manufacturing a cured film, one or more resins are selected from the group consisting of maleimide-containing resins, nadimide-containing resins, itaconimide-containing resins, epoxy resins, (meth)acrylate-containing resins, and phenol-containing resins, wherein maleimide-containing resins, nadimide-containing resins, itaconimide-containing resins, epoxy resins, (meth)acrylate-containing resins, and phenol-containing resins are those disclosed elsewhere in this invention and optionally in amounts disclosed elsewhere in this invention.

[0195] In some embodiments of the method for manufacturing a cured film, one or more imidazoles are those disclosed elsewhere in this invention and are optionally present in amounts disclosed elsewhere in this invention.

[0196] In some embodiments of the method for manufacturing a cured film, one or more inorganic fillers are those disclosed elsewhere in this invention and are optionally present in amounts disclosed elsewhere in this invention.

[0197] In some embodiments of the method for manufacturing a cured film, one or more additives selected from the group consisting of adhesion promoters and film-forming agents are those disclosed elsewhere in this invention and are optionally present in amounts disclosed elsewhere in this invention.

[0198] In some embodiments of the method for manufacturing a cured film, one or more fluxing agents are those disclosed elsewhere in this invention and are optionally present in amounts disclosed elsewhere in this invention.

[0199] In some embodiments of the method for manufacturing a cured film, one or more fluxing agents are compounds having at least one (meth)acrylate group and at least one carboxylic acid group, and are optionally present in amounts disclosed elsewhere in this invention.

[0200] In some embodiments of the method for manufacturing a cured film, one or more fluxing agents are one or more fluxing agents described herein and are optionally present in amounts disclosed elsewhere in this invention.

[0201] In some embodiments, a film produced according to the method for producing a cured film disclosed herein has the physical properties of a film disclosed elsewhere in this invention. For example, in some embodiments, a film produced according to the method for producing a film disclosed herein has one or more of the following: Tg measured by DMA, storage modulus at 25°C, storage modulus at 230°C, storage modulus at 25°C, CTE, DSC initiation temperature measured by DSC at a gradient rate of 10°C / min, and minimum film melt viscosity measured in N2 using a DHR2 rheometer at a gradient rate of 10°C / min.

[0202] In some embodiments, a film prepared according to the method for preparing a film disclosed herein has the following physical properties:

[0203] Tg > 200℃ when measured by dynamic mechanical analysis (DMA),

[0204] Storage modulus at 25℃ < 5.5 GPa,

[0205] Storage modulus at 250℃ > 0.1 GPa, and

[0206] Coefficient of thermal expansion (CTE) < 250 ppm / ℃.

[0207] In some embodiments, a film prepared according to the method for preparing a film disclosed herein has the following physical properties:

[0208] Tg > 230℃ when measured by dynamic mechanical analysis (DMA),

[0209] Storage modulus at 25℃ < 5 GPa,

[0210] Storage modulus at 230℃ > 0.2 GPa, and

[0211] Coefficient of thermal expansion (CTE) < 150 ppm / ℃.

[0212] In some embodiments, a film prepared according to the method for preparing a film disclosed herein has the following physical properties:

[0213] Tg > 240℃ when measured by dynamic mechanical analysis (DMA),

[0214] Storage modulus at 25℃ < 4.8 GPa,

[0215] Storage modulus at 230℃ > 0.25 GPa, and

[0216] Coefficient of thermal expansion (CTE) < 120 ppm / ℃.

[0217] In some embodiments, a film prepared according to the method for preparing a film disclosed herein has the following physical properties:

[0218] Tg 230°C to 280°C when measured by dynamic mechanical analysis (DMA),

[0219] Storage modulus at 25℃ 4.0 GPa to 5.5 GPa, and

[0220] Storage modulus at 230℃ 0.1 GPa to 0.4 GPa.

[0221] In some embodiments, a film prepared according to the method for preparing a film disclosed herein has the following physical properties:

[0222] Tg 230°C to 280°C when measured by dynamic mechanical analysis (DMA),

[0223] Storage modulus at 25℃ 4.0 GPa to 5.5 GPa,

[0224] Storage modulus at 230°C 0.1 GPa to 0.4 GPa, and

[0225] Minimum film melt viscosity of 300 Pa·s to 3,000 Pa·s when measured in N2 using a DHR2 rheometer at an inclined speed of 10°C / min.

[0226] In some embodiments, a film prepared according to the method for preparing a film disclosed herein has the following physical properties:

[0227] Tg 230°C to 280°C when measured by dynamic mechanical analysis (DMA),

[0228] Storage modulus at 25°C 4.0 GPa to 5.0 GPa, storage modulus at 230°C 0.1 GPa to 0.3 GPa, and

[0229] Coefficient of thermal expansion (CTE) 20 ppm / ℃ to 150 ppm / ℃.

[0230] In some embodiments, a film prepared according to the method for preparing a film disclosed herein has the following physical properties:

[0231] Tg 230°C to 280°C when measured by dynamic mechanical analysis (DMA),

[0232] Storage modulus at 25℃ 4.0 GPa to 5.0 GPa,

[0233] Storage modulus at 230℃ 0.2 GPa to 0.3 GPa,

[0234] Coefficient of thermal expansion (CTE) 50 ppm / ℃ to 125 ppm / ℃, and

[0235] Minimum film melt viscosity of 300 Pa·s to 2,000 Pa·s when measured in N2 using a DHR2 rheometer at an inclined speed of 10°C / min.

[0236] Examples

[0237] Exemplary embodiments of a composition according to the present disclosure, including its components, are presented in Table 1, and the characteristics of these exemplary embodiments are likewise. Encapsulated imidazole A and encapsulated imidazole B are both encapsulated imidazoles having latent thermal activity within the meaning of the present disclosure.

[0238] Table 1

[0239]

[0240] The components of four comparative compositions (not within the scope of the present disclosure) (Comparative Examples 1-4) are presented in Table 2, along with the characteristics of these compositions.

[0241] Table 2

[0242]

[0243] As shown in Table 2, two of the comparative compositions (Comparative Example 1 and Comparative Example 4) contain imidazoles (identified as imidazole A and imidazole B), but these imidazoles (imidazole A and imidazole B) are not encapsulated imidazoles and are therefore not encapsulated imidazoles having potential thermal activity within the meaning of this disclosure. Imidazole A is 2-phenylimidazole. Imidazole B is 2-ethyl-4-methyl-1H-imidazole-1-propanenitrile. Two of the comparative compositions (Comparative Example 2 and Comparative Example 3) do not contain any imidazoles. The composition of Example 1 of the present invention demonstrated excellent solder interconnect formation and no material trapping during the hot-press bonding process, and also exhibited excellent high-temperature characteristics with a higher Tg and lower CTE compared to the comparative examples. The compositions of Comparative Examples 1, 2, and 4 were considered unsuitable for the hot-press bonding process. Although the composition of Comparative Example 3 demonstrated excellent solder interconnect formation and no material trapping in hot-press bonding, the compositions of Comparative Examples 1 through 4 all exhibited substandard high-temperature characteristics.

[0244] Therefore, although I do not wish to be bound by theory, compositions containing imidazoles having latent thermal activity, such as encapsulated imidazoles having latent thermal activity, provide characteristics that make the composition more suitable for the hot-press bonding process, including but not limited to the DSC onset temperature, melt viscosity, and ΔT from the DSC onset temperature to the DSC peak temperature, whereas compositions containing imidazoles not having latent thermal activity and compositions lacking imidazoles are considered less suitable for the hot-press bonding process.

Claims

Claim 1 A composition comprising one or more resins selected from the group consisting of epoxy resins and (meth)acrylate-containing resins, one or more encapsulated imidazoles having latent thermal activity, one or more inorganic fillers, and one or more additives selected from the group consisting of adhesion promoters and film-forming agents, wherein: after the composition forms a film, the film has the following physical properties: Tg > 200°C when measured by dynamic mechanical analysis (DMA), storage modulus < 6.5 GPa at 25°C, storage modulus > 0.1 GPa at 25°C, coefficient of thermal expansion (CTE) < 250 ppm / °C, DSC start temperature 120°C to 200°C when measured by differential scanning calorimetry (DSC) at an inclined rate of 10°C / min, and minimum film melt viscosity 10 Pa·s to 10,000 when measured by N2 using a DHR2 rheometer at an inclined rate of 10°C / min. Pa·s; (meth)acrylate resin is represented as follows: Here, n is 0, 1, 2, 3, 4, or 5; a composition in which the epoxy resin is a compound represented by the following: Here, n is 0, 1, 2, 3, 4, or 5, and m is 0, 1, 2, 3, 4, or 5. Claim 2 A composition according to claim 1, further comprising one or more resins selected from the group consisting of maleimide-containing resin, nadimide-containing resin, itaconimide-containing resin, and phenol-containing resin. Claim 3 The composition of claim 1 or 2, wherein, after the composition forms a film, the film has the following physical properties: Tg > 230°C as measured by dynamic mechanical analysis (DMA), storage modulus at 25°C < 5 GPa, storage modulus at 230°C > 0.3 GPa, and coefficient of thermal expansion (CTE) < 120 ppm / °C. Claim 4 In paragraph 2, the maleimide-containing resin is a compound represented by the following, or (wherein: each R is independently selected from the group consisting of H and substituted or unsubstituted alkyl; each m is independently selected from the group consisting of 0, 1, 2, 3, or 4; n is 0, 1, 2, 3, 4, or 5), or a compound represented by (where n is 0, 1, 2, 3, 4, or 5)composition. Claim 5 A composition according to any one of claims 1, 2 and 4, wherein, after the composition forms a film, the film has the following physical properties: a DSC initiation temperature of 120°C to 150°C when measured by differential scanning calorimetry (DSC) at an inclined rate of 10°C / min, and a minimum film melt viscosity of 300 Pa·s to 3,000 Pa·s when measured in N2 using a DHR2 rheometer at an inclined rate of 10°C / min. Claim 6 A composition according to any one of claims 1, 2 and 4, wherein, after the composition forms a film, the film has a ΔT from a DSC initiation temperature of less than 20°C to a DSC peak temperature. Claim 7 A composition according to any one of claims 1, 2 and 4, wherein, after the composition forms a film, the film has a ΔT from a DSC initiation temperature of less than 15°C to a DSC peak temperature. Claim 8 A composition according to any one of claims 1, 2 and 4, wherein, after the composition forms a film, the film has a ΔT from a DSC initiation temperature of less than 10°C to a DSC peak temperature. Claim 9 A composition according to any one of claims 1, 2 and 4, wherein, after the composition forms a film, the film has a ΔT from a DSC initiation temperature of less than 5°C to a DSC peak temperature. Claim 10 A method for manufacturing a cured film comprising the following steps: providing a composition according to any one of claims 1, 2 and 4; casting the composition into a film; and exposing the cast film to an elevated temperature to cure the film. Claim 11 The following steps: providing a composition comprising one or more resins selected from the group consisting of epoxy resins and (meth)acrylate-containing resins, one or more encapsulated imidazoles having latent thermal activity, one or more inorganic fillers, and one or more additives selected from the group consisting of adhesion promoters and film-forming agents; casting the composition into a film; and exposing the cast film to an elevated temperature to cure the film, wherein the (meth)acrylate resin is represented as follows: Here, n is 0, 1, 2, 3, 4, or 5; a method in which the epoxy resin is a compound represented by the following: Here, n is 0, 1, 2, 3, 4, or 5, and m is 0, 1, 2, 3, 4, or 5. Claim 12 A method according to claim 11, wherein the composition further comprises one or more resins selected from the group consisting of maleimide-containing resins, nadimide-containing resins, itaconimide-containing resins, and phenol-containing resins. Claim 13 In paragraph 12, the maleimide-containing resin is a compound represented by the following, or (wherein: each R is independently selected from the group consisting of H and substituted or unsubstituted alkyl; each m is independently selected from the group consisting of 0, 1, 2, 3, or 4; and n is 0, 1, 2, 3, 4, or 5), or a compound represented by (Here, n is 0, 1, 2, 3, 4, or 5) method. Claim 14 A cured film manufactured according to the method of claim 10. Claim 15 A film manufactured according to the method of claim 10, having the following physical properties: Tg > 200°C as measured by dynamic mechanical analysis (DMA), storage modulus < 5.5 GPa at 25°C, storage modulus > 0.1 GPa at 250°C, and coefficient of thermal expansion (CTE) < 250 ppm / °C. Claim 16 A film manufactured according to the method of claim 10, having the following physical properties: Tg > 230°C as measured by dynamic mechanical analysis (DMA), storage modulus < 5 GPa at 25°C, storage modulus > 0.2 GPa at 230°C, and coefficient of thermal expansion (CTE) < 120 ppm / °C. Claim 17 In Clause 14, the film is an underfill film. Claim 18 In paragraph 17, a film that is a wafer-level underfill film (WAUF). Claim 19 delete Claim 20 delete Claim 21 delete

Citation Information

Patent Citations

  • Resin compositions for underfill film for three dimensional through silica via (TSV) packages and compositions useful for the preparation thereof

    US20180319973A1

  • Nonconductive adhesive composition and film and methods of making

    KR1020100100792A

  • Low temperature curing acrylate and maleimide based formulations and methods for use thereof

    US20100063184A1